- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06426836
체외막 산소화(PADECMO) 시 소아 항생제 투여 (PADECMO)
체외막 산소화 시 소아 항생제 투여
Pharmacokinetics of antibiotics in critically ill neonates, infants and children on extracorporeal membrane oxygenation (ECMO).
연구 개요
상태
상세 설명
The study will investigate whether - with the current dosing regimens of meropenem, piperacillin-tazobactam, amoxicillin-clavulanate, cephazolin, vancomycin, amikacin, teicoplanin and ciprofloxacin - pharmacodynamic targets are attained in a national multicentric clinical setting in pediatric patients on ECMO.
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Pieter De Cock, PharmD
- 전화번호: +32 9 332 29 69
- 이메일: pieter.decock@uzgent.be
연구 장소
-
-
-
Ghent, 벨기에, 9000
- 모병
- University Hospital
-
연락하다:
- Pieter De Cock
- 이메일: pieter.decock@uzgent.be
-
Leuven, 벨기에, 3000
- 모병
- Universitair hospital
-
연락하다:
- Debaveye Yves
- 이메일: yves.debaveye@uzleuven.be
-
-
Brussels Capital
-
Brussels, Brussels Capital, 벨기에, 1020
- 모병
- Queen Fabiola Children's University Hospital
-
연락하다:
- Biarent Dominique
- 이메일: dominique.biarent@huderf.be
-
연락하다:
- Vens Daphne
- 이메일: daphnevania.vens@huderf.be
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- patients admitted to the pediatric intensive care unit or cardiac intensive care unit
- patient age : 1,8 kg-15 years
- patient receiving antibiotic treatment (piperacillin-tazobactam, meropenem, amoxicillin-clavulanate, cephazolin, vancomycin, teicoplanin, ciprofloxacin, amikacin)
- intra-arterial or intravenous access other than the drug infusion line available for blood sampling (arterial line is preferred)
- extracorporeal membrane oxygenation circuit
Exclusion Criteria:
- no catheter in place for blood sampling
- absence of parental/patient consent
- known hypersensitivity to beta-lactam antibiotics and ciprofloxacin
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
다른: Amoxicillin-clavulanate
Patients receiving amoxicillin-clavulanate as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care
다른 이름들:
|
|
다른: Piperacillin-tazobactam
Patients receiving piperacillin-tazobactam as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving piperacillin-tazobactam as part of routine clinical care.
다른 이름들:
|
|
다른: Meropenem
Patients receiving meropenem as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving meropenem as part of routine clinical care.
다른 이름들:
|
|
다른: Cefazolin
Patients receiving cefazolin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving cefazolin as part of routine clinical care.
다른 이름들:
|
|
다른: Vancomycin
Patients receiving vancomycin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving vancomycin as part of routine clinical care.
다른 이름들:
|
|
다른: Teicoplanin
Patients receiving teicoplanin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving teicoplanin as part of routine clinical care.
다른 이름들:
|
|
다른: Ciprofloxacin
Patients receiving ciprofloxacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling and urine sampling in patients receiving ciprofloxacin as part of routine clinical care.
다른 이름들:
|
|
다른: Amikacin
Patients receiving amikacin as part of routine clinical care. Study procedure: blood sampling |
blood sampling in patients receiving amikacin as part of routine clinical care.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Amoxicillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amoxicillin, piperacillin, meropenem, cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Cefazolin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Meropenem: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Piperacillin: probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC) of the micro-organism
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
기간: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen off extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
기간: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
기간: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for teicoplanin: probability of target attainment with the target being an Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration Ratio (AUC/MIC)
기간: up to 1 month
|
% of patients in whom an AUC/MIC of 900 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
for amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
기간: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
기간: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
기간: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
기간: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
|
Amikacin: probability of target attainment with the target being a free Area-under-the-Concentration-Time Curve over Minimal Inhibitory Concentration ratio (AUC/MIC)
기간: July 2026
|
% of patients in whom a target fAUC/MIC ratio of 399 is achieved with the current dosing regimen before or after extracorporeal membrane oxygenation in steady-state conditions |
July 2026
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for beta-lactam antibiotics
기간: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a percentage of time during which the unbound concentration remains above the Minimal Inhibitory Concentration (MIC) of the micro-organism of at least 50% and a maximum concentration of 10 x MIC |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for ciprofloxacin
기간: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of ciprofloxacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 86 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for vancomycin
기간: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of vancomycin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a free Area-under the concentration-Time Curve of 200 to 300 |
up to 1 month
|
|
Risk factors for underdosing during extracorporeal membrane oxygenation for teicoplanin
기간: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of teicoplanin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is an Area-under the concentration-Time Curve of 900 |
up to 1 month
|
|
Risk factors for under-and overdosing during extracorporeal membrane oxygenation for amikacin
기간: up to 1 month
|
The impact of demographic, clinical characteristics and ECMO equipment characteristics on the risk of underdosing and overdosing of amikacin will be investigated. The pharmacokinetic/pharmacodynamic target that is used is a peak over Minimal Inhibitory Concentration Ratio of 8 to 10, trough concentration below 5 mg/L and Area under the Concentration Time Curve/MIC>399 |
up to 1 month
|
|
Beta-lactam antibiotics (amoxicillin, piperacillin, meropenem, cefazolin): probability of target attainment with target the % of time during which the unbound drug concentration remains above the Minimal Inhibitory Concentration (fT>MIC)
기간: up to 1 month
|
% of patients for whom a target of fT>MIC of 50% is achieved with current dosing regimens on extracorporeal membrane oxygenation in first dose conditions |
up to 1 month
|
|
Ciprofloxacin: probability of target attainment with the target being the free Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration ratio (fAUC/MIC)
기간: up to 1 month
|
% of patients for whom a fAUC/MIC target>86 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Vancomycin: probability of target attainment with the target being the Area-under the Concentration-Time Curve over Minimal Inhibitory Concentration (AUC/MIC)
기간: up to 1 month
|
% of patients in whom a AUC/MIC target 400-600 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Teicoplanin: probability of target attainment with the target being a mimimal trough concentration
기간: up to 1 month
|
% of patients in whom a trough concentration between 20 to 30 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of target attainment with the target being a peak concentration over Minimal Inhibitory Concentration ratio (peak/MIC)
기간: up to 1 month
|
% of patients in whom a target peak/MIC ratio of 8 is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
|
Amikacin: probability of toxicity threshold attainment with a target being a minimal trough concentration
기간: up to 1 month
|
% of patients in whom the threshold for toxicity concentration>5 mg/L is achieved with the current dosing regimen on extracorporeal membrane oxygenation in first-dose conditions |
up to 1 month
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Annick de Jaeger, MD, University Hospital, Ghent
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
- 펩타이드
- 아미노산, 펩티드 및 단백질
- 황 화합물
- 유기 화학 물질
- 이종 사이 클릭 화합물
- 이종 사이 클릭 화합물, 2- 링
- 이종 사이 클릭 화합물, 융합 링
- 제약 준비
- 조사 기술
- 시편 처리
- 임상 실험실 기술
- 진단 기술 및 절차
- 진단
- 구멍
- 수술 절차, 수술
- 탄수화물
- 글리코 사이드
- 아미드
- 아미노 글리코 시드
- Glycoconjugates
- 약물 조합
- 페니실린 g
- 베타-락탐
- 락탐
- Clavulanic acid
- 클라불란산
- 세 팔로 스포린
- 티아 지인
- 플루오로 퀴놀론
- 4- 퀴놀론
- 퀴놀론
- 퀴놀린
- 설폰
- 카르 바페 em
- 티에나 마이신
- Tazobactam
- 페니 실란산
- 파이퍼 라실린
- 글리코 펩티드
- 암피실린
- 페니실린
- 카나마이신
- 리포지 글리코 펩티드
- 아목시실린
- 메로페넴
- 피페라실린, 타조박탐 약물 조합
- 반코마이신
- 아미카신
- 세파졸린
- 아목시실린-클라불란산 칼륨 조합
- 테이코플라닌
- 시프로플록사신
- 혈액 표본 수집
기타 연구 ID 번호
- BC-03512 (EC 2015/0529)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .